Nine progressions to AML and three to myelodysplastic syndrome (MDS) were registered mainly in patients with TP53 disruption/aneuploidy or aberrations in spliceosome/chromatin genes (p < 0.0001, Fig. 2d). The gene discussed is TP53; the disease is myelodysplastic syndrome.